105 related articles for article (PubMed ID: 27725222)
1. Prognostic impact of serum soluble LR11 in newly diagnosed diffuse large B-cell lymphoma: A multicenter prospective analysis.
Sugita Y; Ohwada C; Kawaguchi T; Muto T; Tsukamoto S; Takeda Y; Mimura N; Takeuchi M; Sakaida E; Shimizu N; Tanaka H; Abe D; Fukazawa M; Sugawara T; Aotsuka N; Nishiwaki K; Shono K; Ebinuma H; Fujimura K; Bujo H; Yokote K; Nakaseko C
Clin Chim Acta; 2016 Dec; 463():47-52. PubMed ID: 27725222
[TBL] [Abstract][Full Text] [Related]
2. Circulating LR11 is a novel soluble-receptor marker for early-stage clinical conditions in patients with non-Hodgkin's lymphoma.
Fujimura K; Ebinuma H; Fukamachi I; Ohwada C; Kawaguchi T; Shimizu N; Takeuchi M; Sakaida E; Jiang M; Nakaseko C; Bujo H
Clin Chim Acta; 2014 Mar; 430():48-54. PubMed ID: 24394293
[TBL] [Abstract][Full Text] [Related]
3. Circulating soluble form of LR11, a regulator of smooth muscle cell migration, is a novel marker for intima-media thickness of carotid arteries in type 2 diabetes.
Jin W; Jiang M; Han X; Han X; Murano T; Hiruta N; Ebinuma H; Piao L; Schneider WJ; Bujo H
Clin Chim Acta; 2016 Jun; 457():137-41. PubMed ID: 27095609
[TBL] [Abstract][Full Text] [Related]
4. Serum soluble LR11, a novel tumor derived biomarker associated with the outcome of patients with diffuse large B-cell lymphoma.
Ohwada C; Yamazaki A; Kawaguchi T; Sugita Y; Takeuchi M; Shimizu N; Sakaida E; Takeda Y; Tsukamoto S; Muto T; Jiang M; Higashi M; Yokote K; Tamaru J; Bujo H; Nakaseko C
Leuk Lymphoma; 2015; 56(10):2982-5. PubMed ID: 25676033
[No Abstract] [Full Text] [Related]
5. Circulating soluble LR11/SorLA levels are highly increased and ameliorated by chemotherapy in acute leukemias.
Sakai S; Nakaseko C; Takeuchi M; Ohwada C; Shimizu N; Tsukamoto S; Kawaguchi T; Jiang M; Sato Y; Ebinuma H; Yokote K; Iwama A; Fukamachi I; Schneider WJ; Saito Y; Bujo H
Clin Chim Acta; 2012 Oct; 413(19-20):1542-8. PubMed ID: 22750733
[TBL] [Abstract][Full Text] [Related]
6. Levels of circulating soluble LR11, a regulator of smooth muscle cell migration, are highly associated with atherosclerotic plaques in patients with carotid artery stenosis.
Harada M; Jiang M; Terai K; Ebinuma H; Hiruta N; Schneider WJ; Sugo N; Nagao T; Bujo H
Clin Chim Acta; 2019 Mar; 490():69-76. PubMed ID: 30550937
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of circulating soluble LR11 on long-term clinical outcomes in patients with coronary artery disease.
Ogita M; Miyauchi K; Kasai T; Tsuboi S; Wada H; Naito R; Konishi H; Dohi T; Tamura H; Okazaki S; Yanagisawa N; Shimada K; Suwa S; Jiang M; Bujo H; Daida H
Atherosclerosis; 2016 Jan; 244():216-21. PubMed ID: 26687467
[TBL] [Abstract][Full Text] [Related]
8. Increased circulating soluble LR11 in patients with acute coronary syndrome.
Ogita M; Miyauchi K; Dohi T; Tsuboi S; Miyazaki T; Yokoyama T; Yokoyama K; Shimada K; Kurata T; Jiang M; Bujo H; Daida H
Clin Chim Acta; 2013 Jan; 415():191-4. PubMed ID: 23127357
[TBL] [Abstract][Full Text] [Related]
9. G-CSF induces the release of the soluble form of LR11, a regulator of myeloid cell mobilization in bone marrow.
Shimizu N; Nakaseko C; Jiang M; Nishii K; Yokote K; Iseki T; Higashi M; Tamaru J; Schneider WJ; Bujo H
Ann Hematol; 2014 Jul; 93(7):1111-22. PubMed ID: 24577511
[TBL] [Abstract][Full Text] [Related]
10. [Novel biomarker for pathological immature cells--soluble form of LR11].
Bujo H
Rinsho Byori; 2012 May; 60(5):469-76. PubMed ID: 22774576
[TBL] [Abstract][Full Text] [Related]
11. Enhanced circulating soluble LR11 in patients with diabetic retinopathy.
Takahashi M; Bujo H; Shiba T; Jiang M; Maeno T; Shirai K
Am J Ophthalmol; 2012 Jul; 154(1):187-92. PubMed ID: 22541650
[TBL] [Abstract][Full Text] [Related]
12. Soluble LR11 competes with amyloid β in binding to cerebrospinal fluid-high-density lipoprotein.
Yano K; Hirayama S; Misawa N; Furuta A; Ueno T; Motoi Y; Seino U; Ebinuma H; Ikeuchi T; Schneider WJ; Bujo H; Miida T
Clin Chim Acta; 2019 Feb; 489():29-34. PubMed ID: 30448281
[TBL] [Abstract][Full Text] [Related]
13. Enhanced circulating soluble LR11 in patients with coronary organic stenosis.
Takahashi M; Bujo H; Jiang M; Noike H; Saito Y; Shirai K
Atherosclerosis; 2010 Jun; 210(2):581-4. PubMed ID: 20047743
[TBL] [Abstract][Full Text] [Related]
14. LR11/SorLA links triglyceride-rich lipoproteins to risk of developing cardiovascular disease in FH patients.
Vongpromek R; Bujo H; Hoekstra M; Schneider WJ; van der Zee L; Schinkel AF; Korporaal SJ; Dik WA; Ebinuma H; Jiang M; Verhoeven AJ; Sijbrands EJ; Mulder MT
Atherosclerosis; 2015 Dec; 243(2):429-37. PubMed ID: 26520897
[TBL] [Abstract][Full Text] [Related]
15. Development of an immunoassay for the quantification of soluble LR11, a circulating marker of atherosclerosis.
Matsuo M; Ebinuma H; Fukamachi I; Jiang M; Bujo H; Saito Y
Clin Chem; 2009 Oct; 55(10):1801-8. PubMed ID: 19661140
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of measuring soluble LR11, a circulating marker of atherosclerosis and HbA1c in familial hypercholesterolemia.
Nohara A; Kobayashi J; Kawashiri MA; Tada H; Inazu A; Jiang M; Mabuchi H; Bujo H
Clin Biochem; 2014 Sep; 47(13-14):1326-8. PubMed ID: 24859021
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of bone marrow infiltration detected by PET-CT in newly diagnosed diffuse large B cell lymphoma.
Liang JH; Sun J; Wang L; Fan L; Chen YY; Qu XY; Li TN; Li JY; Xu W
Oncotarget; 2016 Apr; 7(14):19072-80. PubMed ID: 26919239
[TBL] [Abstract][Full Text] [Related]
18. Soluble LR11 is a novel biomarker for vascular lesions late after Kawasaki disease.
Watanabe K; Suzuki H; Jiang M; Haniu H; Numano F; Hoshina S; Saitoh A; Uchiyama M; Bujo H
Atherosclerosis; 2016 Mar; 246():94-7. PubMed ID: 26761773
[TBL] [Abstract][Full Text] [Related]
19. Expression of BAFF-R, but not BAFF, is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP.
Wang Y; Li YJ; Jiang WQ; Rao HL; Huang JJ; Xia Y; Bi X; Sun P; Huang HQ; Lin TY; Guan ZZ; Li ZM
Ann Hematol; 2015 Nov; 94(11):1865-73. PubMed ID: 26327569
[TBL] [Abstract][Full Text] [Related]
20. Circulating soluble LR11, a novel marker of smooth muscle cell proliferation, is enhanced after coronary stenting in response to vascular injury.
Ogita M; Miyauchi K; Jiang M; Kasai T; Tsuboi S; Naito R; Konishi H; Dohi T; Yokoyama T; Okazaki S; Shimada K; Bujo H; Daida H
Atherosclerosis; 2014 Nov; 237(1):374-8. PubMed ID: 25443876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
